ConverGene
ConverGene, founded in 2011, specializes in small molecule drug discovery for cancer treatment, leveraging rational drug design.
Founded
2011ConverGene, founded in 2011, specializes in small molecule drug discovery for cancer treatment, leveraging rational drug design.
ConverGene, founded in 2011, is a small molecule drug discovery company focused on developing therapeutics with novel mechanisms of action for cancer patients with limited or no treatment options. The company leverages rational drug design to target BET proteins, which are believed to be crucial for the epigenetic control of MYC. ConverGene aims to create first-in-class dual inhibitors targeting both BET bromodomains and Dopamine Receptor 2, addressing rare diseases and unmet medical needs.
The founding team comprises six leaders in genomics and personalized medicine, bringing extensive medicinal chemistry expertise. ConverGene has attracted notable investors and collaborators in the biotech industry, contributing to its innovative research and development efforts. The company's key achievements include advancing its drug candidates through preclinical stages and establishing strategic partnerships. ConverGene's impact lies in its potential to offer groundbreaking treatments for patients who currently have few therapeutic options.
Companies similar to ConverGene include BridGene Biosciences, Convergent Therapeutics, Ligon Discovery and Actio Biosciences.
ConverGene was founded in 2011.
ConverGene's headquarters is located in Cambridge, MA, US.
ConverGene's most recent funding round was for $850k (USD) in April 2014.
As of Apr 8, 2014, ConverGene has disclosed funding of $850k (USD). Undisclosed round amounts are excluded.
ConverGene has 6 employees as of Feb 5, 2024.
Actio Biosciences
actiobio.com
